Suppr超能文献

辛伐他汀在脊髓创伤实验模型中的抗炎作用:涉及 PPAR-α。

Anti-inflammatory effect of simvastatin in an experimental model of spinal cord trauma: involvement of PPAR-α.

机构信息

Department of Clinical and Experimental Medicine and Pharmacology, School of Medicine, University of Messina, 98125 Messina, Italy.

出版信息

J Neuroinflammation. 2012 Apr 26;9:81. doi: 10.1186/1742-2094-9-81.

Abstract

BACKGROUND

Statins such as simvastatin are inhibitors of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase used in the prevention of cardiovascular disease. In addition to their cholesterol-lowering activities, statins exert pleiotropic anti-inflammatory effects, which might contribute to their beneficial effects on lipid-unrelated inflammatory diseases. Recently it has been demonstrated that the peroxisome proliferator-activated receptor (PPAR)-α mediates anti-inflammatory effects of simvastatin in vivo models of acute inflammation. Moreover, previous results suggest that PPAR-α plays a role in control of secondary inflammatory process associated with spinal cord injury (SCI).

METHODS

With the aim to characterize the role of PPAR-α in simvastatin activity, we tested the efficacy of simvastatin (10 mg/kg dissolved in saline i.p. 1 h and 6 h after the trauma) in an experimental model of SCI induced in mice by extradural compression of the spinal cord (T6-T7 level) using an aneurysm clip with a closing force of 24 g via a four-level T5-T8 laminectomy, and comparing mice lacking PPAR-α (PPAR-α KO) with wild type (WT) mice. In order to elucidate whether the effects of simvastatin are due to activation of the PPAR-α, we also investigated the effect of a PPAR-α antagonist, GW6471 (1 mg/kg administered i.p. 30 min prior treatment with simvastatin) on the protective effects of on simvastatin.

RESULTS

Results indicate that simvastatin activity is weakened in PPAR-α KO mice, as compared to WT controls. In particular, simvastatin was less effective in PPAR-α KO, compared to WT mice, as evaluated by inhibition of the degree of spinal cord inflammation, neutrophil infiltration, nitrotyrosine formation, pro-inflammmatory cytokine expression, nuclear factor (NF)-κB activation, inducible nitric-oxide synthase (iNOS) expression, and apoptosis. In addition we demonstrated that GW6471 significantly antagonized the effect of the statin and thus abolished the protective effect.

CONCLUSIONS

This study indicates that PPAR-α can contribute to the anti-inflammatory activity of simvastatin in SCI.

摘要

背景

辛伐他汀等他汀类药物是 3-羟基-3-甲基戊二酰辅酶 A(HMG-CoA)还原酶的抑制剂,用于预防心血管疾病。除了降低胆固醇的作用外,他汀类药物还具有多效抗炎作用,这可能有助于它们对与脂质无关的炎症性疾病产生有益影响。最近已经证明,过氧化物酶体增殖物激活受体(PPAR)-α在体内急性炎症模型中介导辛伐他汀的抗炎作用。此外,先前的结果表明,PPAR-α在控制与脊髓损伤(SCI)相关的继发性炎症过程中发挥作用。

方法

为了研究 PPAR-α在辛伐他汀活性中的作用,我们在通过 T5-T8 椎板切除术进行四级 T5-T8 椎板切除术,使用闭合力为 24g 的动脉瘤夹对脊髓(T6-T7 水平)进行硬膜外压迫诱导的 SCI 实验模型中,测试了辛伐他汀(10mg/kg 在创伤后 1 小时和 6 小时溶于生理盐水中腹腔注射)的疗效,并将缺乏 PPAR-α 的小鼠(PPAR-α KO)与野生型(WT)小鼠进行比较。为了阐明辛伐他汀的作用是否归因于 PPAR-α 的激活,我们还研究了 PPAR-α 拮抗剂 GW6471(辛伐他汀治疗前 30 分钟腹腔注射 1mg/kg)对辛伐他汀保护作用的影响。

结果

结果表明,与 WT 对照组相比,辛伐他汀在 PPAR-α KO 小鼠中的活性减弱。具体而言,与 WT 小鼠相比,辛伐他汀在 PPAR-α KO 小鼠中的作用较弱,如通过抑制脊髓炎症程度、中性粒细胞浸润、硝基酪氨酸形成、促炎细胞因子表达、核因子(NF)-κB 激活、诱导型一氧化氮合酶(iNOS)表达和细胞凋亡来评估。此外,我们证明 GW6471 可显著拮抗他汀类药物的作用,从而消除其保护作用。

结论

本研究表明,PPAR-α 可有助于辛伐他汀在 SCI 中的抗炎作用。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验